Category Archives: Stem Cell Research

Stem Cell Cartilage Regeneration Marketreport studies the Stem Cell Cartilage Regeneration with many aspects of the industry like the market size, market status, market trends and forecast, the report also provides brief information of the competitors and the specific growth opportunities with key market drivers. Find the complete Stem Cell Cartilage RegenerationMarket analysis segmented by companies, region, type and applications in the report.

Scope of Stem Cell Cartilage Regeneration:Stem Cell Cartilage RegenerationMarket report evaluates the growth rate and the market value based on market dynamics, growth inducing factors. Complete knowledge is based on the latest industry news, opportunities, and trends. The report contains a comprehensive market analysis and vendor landscape in addition to a SWOT analysis of the key vendors.

We Do Offer Sample of this report. Kindly go through the follow information in order to access the report.

** Note This report sample includes:

Receive Sample of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/2448

Major companies in Stem Cell Cartilage RegenerationMarket are:Theracell Advanced Biotechnology Ltd., Orthocell Ltd., Xintela AB, CellGenix GmbH, Merck KGaA, Osiris Therapeutics, Inc., BioTissue SA, and Vericel Corporation.

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key players and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

The complete research assessment of Global Stem Cell Cartilage Regeneration Market provides granular analysis of industrys new upgrades, censorious trends, current market pilots, challenges, and standardization and technical domain.

This report also splits the market by region:

Americas, United States, Canada, Mexico, Brazil, APAC, China, Japan, Korea, Southeast Asia, India, Australia, Europe, Germany, France, UK, Italy, Russia, Spain, Middle East and Africa, Egypt, South Africa, Israel, Turkey, GCC Countries

Global Stem Cell Cartilage Regeneration Market 2020Key Insights:

Research and analyze the Stem Cell Cartilage Regeneration Market standing and future forecast associated with production, Stem Cell Cartilage Regeneration price structure, consumption, and Stem Cell Cartilage Regeneration Market historical knowledge.

The report understands the structure of Stem Cell Cartilage Regeneration trade by distinctive its varied segments and sub-segments.

Market split the breakdown knowledge by company, products, end-user, and prime countries, Stem Cell Cartilage Regeneration Market history knowledge from 2015 to 2019 and forecast to 2026.

Analysis of Stem Cell Cartilage Regeneration Market regarding individual growth trends, future prospects, and their contribution to the overall Stem Cell Cartilage Regeneration Market.

Global Stem Cell Cartilage Regeneration Market 2020 report analyzes competitive expansions like agreements, new product launches, and Stem Cell Cartilage Regeneration Market acquisition.

Research report target the key international Stem Cell Cartilage Regeneration players to characterize sales volume, Stem Cell Cartilage Regeneration revenue, growth potential, drivers, SWOT analysis, and Stem Cell Cartilage Regeneration development plans in coming years.

**Note:Access insightful study with over 150+ pages, list of tables & figures, profiling 20+ companies.

Direct Buy Copy of This Business Research Report: https://www.coherentmarketinsights.com/insight/buy-now/2448

Highlights of the Global Stem Cell Cartilage Regeneration report:

The report has been collated on the basis of synthesis, analysis, and interpretation of data accumulated with regards to the parent market from various resources. Additionally, study has been made of the economic conditions and other economic indicators and factors to evaluate their respective impact on the Stem Cell Cartilage Regeneration Market, along with the present impact, so as to make strategic and informed forecasts about the scenarios in the market. This is primarily because of the untapped potentials present in the developing nations, in terms of product pricing and revenue generation.

About us:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. ShahCoherent Market Insights1001 4th Ave, #3200Seattle, WA 98154Phone: US +12067016702 / UK +4402081334027Email: [emailprotected]

Visit This Blog: https://globalhealthcareinsights.wordpress.com/blog

The rest is here:
Stem Cell Cartilage Regeneration Market: Analysis of Prevailing Trends In The Parent Market 2026 - Cole of Duty

This report studies the Stem Cell Cartilage Regenerationmarket status and outlook of global and United States, from angles of players, regions, product types and end industries; this report analyzes the top players in global and United States market, and splits the Stem Cell Cartilage Regenerationmarket by product type and applications/end industries.

Among the several objectives of the research study, it provides a detailed description of recent trends, technological advancements, and various platforms, which further are beneficial to improve the performance of the companies.

Click here for free sample copy with TOC, tables, charts, graphs of the report @https://www.qyreports.com/request-sample/?report-id=131886

Key players in global Stem Cell Cartilage Regeneration market include: Anika Therapeutics, Biomet, BioTissue Technologies, DePuy (Johnson & Johnson), Genzyme, CellGenix, EMD Serono, Sanofi Aventis, Smith & Nephew, Zimmer

Discount Available @ https://www.qyreports.com/ask-for-discount/?report-id=131886

Reasons for Buying this Report

This report provides pin-point analysis for changing competitive dynamics

It provides a forward looking perspective on different factors driving or restraining market growth

It provides a six-year forecast assessed on the basis of how the market is predicted to grow

It helps in understanding the key product segments and their future

It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors

It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

It provides distinctive graphics and exemplified analysis of major market segments

The report can answer the following questions:

Get a Customized Report in your Inbox within 24 hours, visit @ https://www.qyreports.com/enquiry-before-buying/?report-id=131886

A judge has said that Johnson & Johnson is supposed to pay $8 billion in the case of male breast growth linked to Risperdal. Philadelphia judge said that Johnson & Johnson must pay $8 billion in damages to a man

Read more from the original source:
Stem Cell Cartilage Regeneration Market 2020 by Manufacturers, Regions, Product Types, Application, Sales, Revenue and Forecast to 2027 | Anika...

Allogeneic Stem Cell Therapy Market 2018: Global Industry Insights by Global Players, Regional Segmentation, Growth, Applications, Major Drivers, Value and Foreseen till 2024

The report provides both quantitative and qualitative information of global Allogeneic Stem Cell Therapy market for period of 2018 to 2025. As per the analysis provided in the report, the global market of Allogeneic Stem Cell Therapy is estimated to growth at a CAGR of _% during the forecast period 2018 to 2025 and is expected to rise to USD _ million/billion by the end of year 2025. In the year 2016, the global Allogeneic Stem Cell Therapy market was valued at USD _ million/billion.

This research report based on Allogeneic Stem Cell Therapy market and available with Market Study Report includes latest and upcoming industry trends in addition to the global spectrum of the Allogeneic Stem Cell Therapy market that includes numerous regions. Likewise, the report also expands on intricate details pertaining to contributions by key players, demand and supply analysis as well as market share growth of the Allogeneic Stem Cell Therapy industry.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2632386&source=atm

Allogeneic Stem Cell Therapy Market Overview:

The Research projects that the Allogeneic Stem Cell Therapy market size will grow from in 2018 to by 2024, at an estimated CAGR of XX%. The base year considered for the study is 2018, and the market size is projected from 2018 to 2024.

The report on the Allogeneic Stem Cell Therapy market provides a birds eye view of the current proceeding within the Allogeneic Stem Cell Therapy market. Further, the report also takes into account the impact of the novel COVID-19 pandemic on the Allogeneic Stem Cell Therapy market and offers a clear assessment of the projected market fluctuations during the forecast period. The different factors that are likely to impact the overall dynamics of the Allogeneic Stem Cell Therapy market over the forecast period (2019-2029) including the current trends, growth opportunities, restraining factors, and more are discussed in detail in the market study.

Leading manufacturers of Allogeneic Stem Cell Therapy Market:

The key players covered in this studyEscape Therapeutics, Inc.Lonza Group Ltd.Osiris Therapeutics (Smith & Nephew)NuVasiveChiesi PharmaceuticalsJCR PharmaceuticalPharmicellAnterogenMolMed S.p.A.Takeda (TiGenix)

Market segment by Type, the product can be split intoAdult Stem Cell TherapyHuman Embryonic Stem Cell TherapyInduced Pluripotent Stem Cell TherapyOthersMarket segment by Application, split intoMusculoskeletal DisorderWounds & InjuriesCardiovascular DiseasesOthers

Market segment by Regions/Countries, this report coversNorth AmericaEuropeChinaJapanSouth Korea

The study objectives of this report are:To analyze global Allogeneic Stem Cell Therapy status, future forecast, growth opportunity, key market and key players.To present the Allogeneic Stem Cell Therapy development in North America, Europe, China, Japan and South Korea.To strategically profile the key players and comprehensively analyze their development plan and strategies.To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Allogeneic Stem Cell Therapy are as follows:History Year: 2015-2019Base Year: 2019Estimated Year: 2020Forecast Year 2020 to 2026For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.marketresearchhub.com/enquiry.php?type=E&repid=2632386&source=atm

Some important highlights from the report include:

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2632386&licType=S&source=atm

The Questions Answered by Allogeneic Stem Cell Therapy Market Report:

And Many More.

Follow this link:
COVID-19: Responding to the business impacts of Allogeneic Stem Cell Therapy Revenue, Opportunity, Forecast and Value Chain 2019-2020 - Cole of Duty

The research report on theStem Cell Concentration System marketis a specialized and in-depth industry research dealing with all technical and profitable business outlook. In the dossier all the historical and current trends of Stem Cell Concentration System market is discussed comprehensively. It also showcases the trends that are anticipated for the Stem Cell Concentration System market during the forecast period.

The industry statistics that are encompassed within this report is not only global but also deals with regional and country analysis. This helps the user acquire an extensive perspective about the Stem Cell Concentration System market. The statistical data that is provided is further supported with thorough qualitative information. The aspects that directly or indirectly impact the Stem Cell Concentration System market are exemplified through attributes such as drivers, restraints, opportunities, and the market challenges.

FREE Request Sample is Available@https://www.marketdataanalytics.biz/global-stem-cell-concentration-system-market-industry-trends-and-21220.html#request-sample

The research study encompasses all the trusted models and industry analysis which prove useful for the market players to plan out the business strategies that will further help for the market development. The report also offers exhaustive competitive landscape of the market players. The major market players that are incorporated within this report areEmCyte, Zimmer Biomet, Argos Technologies, Perkin Elmer, Arthrex, Avita Medical, Teleflex, Terumo.

The market segments that are included in the report are{Syringes, Bone Marrow Collection Needles, Anticoagulant and Concentrating Devices}; {Hospital, Clinic, Diagnostic Laboratories}. Along with major segments the sub-segments of the Stem Cell Concentration System market is also included. The regional segmentation of the market includes North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. The major countries that are included are US, Canada, Germany, UK, China, Japan, Brazil, Mexico, among others. The study evaluates the dominance of the market in each region which helps the clients to evaluate the market demand and share on the global platform.

Read Detailed Index of full Research Study at::https://www.marketdataanalytics.biz/global-stem-cell-concentration-system-market-industry-trends-and-21220.html

Details about the market players are profiled at the end. It includes all the minute information about the organization such as its headquarter location, the sales and the production details, recent product developments, and the company strategies.

Main market perceptions consist of the following:

1. The survey of Stem Cell Concentration System delivers market size and growth rate for the forecast period 2020-2026.

2. It presents detailed understandings into ongoing industry trends, trend prediction, and growth drivers about the Stem Cell Concentration System.

3. It offers an independent review of market sectors and the regional outlook of Stem Cell Concentration System.

4. The report provides a detailed overview of the supplier landscape, combative analysis, and key market strategies to gain an advantage on competing companies.

For Any Query Regarding the Stem Cell Concentration System Market Report? Contact Us at:https://www.marketdataanalytics.biz/global-stem-cell-concentration-system-market-industry-trends-and-21220.html#inquiry-for-buying

See the original post:
Coronavirus (COVID-19) Impact On Global Stem Cell Concentration System Market 2020 Analysis By Top Key Players | EmCyte, Zimmer Biomet, Argos...

The Stem Cell And Platelet Rich Plasma (PRP) Alopecia Therapies Market is analyzed in depth in the report, with the main aim of providing precise market data and useful recommendations so that players can achieve strong growth in the future. The report is compiled by experienced experts and market analysts, which makes it very authentic and reliable. Readers have an in-depth analysis of historical and future market scenarios to gain a good understanding of market competition and other important issues. The report provides in-depth research on market dynamics, key segments, key players and various regional markets. It is a complete set of in-depth analysis and research on the Stem Cell And Platelet Rich Plasma (PRP) Alopecia Therapies market.

The report authors highlighted the lucrative business prospects, catchy trends, regulatory situations and Stem Cell And Platelet Rich Plasma (PRP) Alopecia Therapies market price scenarios. It is important to note that the report contains a detailed analysis of the macroeconomic and microeconomic factors affecting the growth of the Stem Cell And Platelet Rich Plasma (PRP) Alopecia Therapies market. It is divided into several sections and chapters so that you can easily understand all aspects of the Stem Cell And Platelet Rich Plasma (PRP) Alopecia Therapies market. Market participants can use the report to take a look at the future of the Stem Cell And Platelet Rich Plasma (PRP) Alopecia Therapies market and make significant changes to their operating style and marketing tactics to achieve sustainable growth.

Get | Download Sample Copy of Stem Cell And Platelet Rich Plasma (PRP) Alopecia Therapies Market Research Report @ https://www.marketresearchintellect.com/download-sample/?rid=174132&utm_source=NDN&utm_medium=888

Top Key Players of the Stem Cell And Platelet Rich Plasma (PRP) Alopecia Therapies Market:

Market Competition

The competitive landscape of the Stem Cell And Platelet Rich Plasma (PRP) Alopecia Therapies market is discussed in detail in the report, focusing on the latest developments, the future plans of the main players and the most important growth strategies they have adopted. The analysts who wrote the report presented almost all of the key players in the Stem Cell And Platelet Rich Plasma (PRP) Alopecia Therapies market and highlighted their critical business aspects such as production, business areas and product portfolio. All of the companies analyzed in the report are examined according to key factors such as market share, market growth, company size, production volume, sales and profits.

Market Segmentation

The report provides an excellent overview of the main Stem Cell And Platelet Rich Plasma (PRP) Alopecia Therapies market segments, focusing on their CAGR, market size, market share and potential for future growth. The Stem Cell And Platelet Rich Plasma (PRP) Alopecia Therapies market is mainly divided by product type, application and region. Each segment of these categories is thoroughly researched to familiarize you with its growth prospects and key trends. Segment analysis is very important to identify the most significant pockets of growth in a global market. The report provides specific information on market growth and demand for various products and applications so that players can focus on profitable sectors of the Stem Cell And Platelet Rich Plasma (PRP) Alopecia Therapies market.

By Product:

By Applications:

Key Questions Answered

The report answers important questions that companies may have when operating in the Stem Cell And Platelet Rich Plasma (PRP) Alopecia Therapies market. Some of the questions are given below:

Answering such types of questions can be very helpful for players to clear their doubts when implementing their strategies to gain growth in the Stem Cell And Platelet Rich Plasma (PRP) Alopecia Therapies market. The report offers a transparent picture of the real situation of the Stem Cell And Platelet Rich Plasma (PRP) Alopecia Therapies market so that companies can operate more effectively. It can be customized according to the needs of readers for better understanding of the Stem Cell And Platelet Rich Plasma (PRP) Alopecia Therapies market.

Request Customization of Report @ https://www.marketresearchintellect.com/need-customization/?rid=174132&utm_source=NDN&utm_medium=888

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Tags: Stem Cell And Platelet Rich Plasma (PRP) Alopecia Therapies Market Size, Stem Cell And Platelet Rich Plasma (PRP) Alopecia Therapies Market Trends, Stem Cell And Platelet Rich Plasma (PRP) Alopecia Therapies Market Growth, Stem Cell And Platelet Rich Plasma (PRP) Alopecia Therapies Market Forecast, Stem Cell And Platelet Rich Plasma (PRP) Alopecia Therapies Market Analysis Sarkari result, Government Jobs, Sarkari naukri, NMK, Majhi Naukri,

Follow this link:
Stem Cell And Platelet Rich Plasma (PRP) Alopecia Therapies Market Research Report 2020: Key Players, Applications, Drivers, Trends and Forecast to...

New research has identified two actives that can prevent stem cell decline as we age and increase collagen 17 levels in cells. It was published in Nature last year and has just been covered in Scientific American. The study was described as elegant by a prominent dermatologist, not involved in the project. As I am always on the look out for next big thing in antiaging skincare, I pounced.

Ill cut straight to the car chase. The two actives are Y27632 and apocynin and I was curious to see if they could be tracked down outside of a lab and, perhaps, in our potions and lotions. The first is a chemical that I havent been able to track down. Happily, I had better luck with apocynin.

Apocynin has been identified in a specific strain of cannabis, but also in cloudberry. And rubus chamaemorus (AKA cloudberry) seed oil is in a facial oil by Keracell. Ill post a link at the end of this article.

So, how do Y27632 and apocynin work? Emi Nishimura, a professor of stem cell biology at Tokyo Medical and Dental University in Japan, revealed that aging and UV exposure deplete stem cells of a crucial collagen protein. Heres what happens.

As part of normal skin health, the top layer of the epidermis is constantly being sloughed off and replaced from a self-replenishing pool of stem cells in the basal layer. These stem cells have roots that anchor them to a thin piece of tissue called the basement membrane that connects the epidermis and the dermis. Only when tethered can they replicate and mature into another type of cell.

This is where collagen 17 comes in. This collagen protein does the tethering (see the "adhesive molecule" in the illustration above), rooting the stem cell to the basement membrane. As stem cells become damaged, they lose precious amounts of collagen 17. The more protein they lose, the weaker their bond to the basement membrane, until eventually they are forced out by neighboring healthy cells.

Thats why this study is potentially a breakthrough. It has identified the process, the key protein that needs to be replenished and the chemicals that might just be able to do that.

You can find rubus chamaemorus (AKA cloudberry) seed oil and a potential source of apocynin in KERACELL Liquid Gold Enriching Elixir ($160 in the shop).

Become a member to read this article in full

Your membership includes:

Continued here:
New research could be a breakthough in collagen and stem cell research - Truth In Aging

MD Stem Cells reports results for Dry AMD from their clinical study SCOTS - the Stem Cell Ophthalmology Treatment Study. 63% of treated and evaluated eyes achieved improvement in vision while an additional 34% had vision remain stable in follow up. No complications occurred. Results were statistically significant.

Westport, CT, April 18, 2020 --(PR.com)-- Age Related Macular Degeneration - specifically dry AMD - will affect almost 200 million people worldwide in 2020. An approach, pioneered by MD Stem Cells, using bone marrow stem cells from the actual patient has now shown visual improvement for 63% of dry AMD eyes and stability in another 34%, demonstrating statistical significance in helping patients with this blinding disease. Results were recently published in the Medicines Journal - a highly regarded international medical journal. The title of the paper: Stem Cell Ophthalmology Treatment Study (SCOTS): Bone Marrow-Derived Stem Cells in the Treatment of Age-Related Macular Degeneration.

There is no FDA approved medication for treating dry AMD. Certain vitamins may reduce the risk of bleeding or wet AMD. But vitamins do not appear to stop the relentless loss of retinal cells and vision called geographic atrophy (GA) from AMD.

The highlight of the MD Stem Cell report was that 63% of dry AMD eyes treated and followed had vision improvement. This ranged from 2.5% to 44.6% with an average of 27.6% on a scientific vision scale called LogMAR. An additional 34% of eyes remained stable for the follow up period- important because many of the eyes had previously been losing vision. The findings were highly statistically significant with p < 0.001 meaning that the results overwhelmingly met that medical standard and confirming that the BMSC treatment was responsible for the improvements seen.

The Stem Cell Treatment Ophthalmology Study- both SCOTS and SCOTS2 - has been treating many different eye diseases since 2013 using the patients own bone marrow stem cells (BMSC) injected in the orbit around the eye. The study is Institutional Board Approved and National Institutes of Health registered on http://www.clinicaltrials.gov NCT 03011541. The physicians involved with MD Stem Cells now have 14 world class medical and scientific publications primarily reporting their clinical results in ophthalmology. This is vastly more than any other stem cell research group working with eye disease and should be reassuring to patients and health care providers seeking treatment options. Different optic nerve diseases, NAION, LHON, DOA, optic atrophy; as well as several retinal diseases including Retinitis Pigmentosa, Ushers and now AMD have all shown benefit. MD Stem Cells has worked to achieve the safest, most effective approach to dry AMD using BMSC - with gratifying success.

Following multiple patient treatments and over a dozen peer-reviewed papers, our studies have shown that a patients own bone marrow stem cells (BMSC) can have positive effects on different retinal and optic nerve diseases, explains Dr. Levy, CEO and Chief Science Officer for MD Stem Cells. As we have continued the study, other researchers have published numerous papers revealing how this may be occurring: release of exosomes with neurotrophic factors helping neurons and photoreceptors, transfer of cytoplasmic structures such as mitochondria to injured cells, and transdifferentiation of BMSC into neurons.

Dr. Levy concludes: The research has shown that patients with dry AMD choosing to participate in the SCOTS 2 may have a significant likelihood of either improving or stabilizing their vision.

Patients may receive information about SCOTS 2 by emailing stevenlevy@mdstemcells.com, using the contact us page on http://www.mdstemcellscom, or calling 203-423-9494. The Stem Cell Ophthalmology Study 2 is enrolling patients with different retina and optic nerve diseases. MD Stem Cells has no grant support and is not a pharmaceutical company; these are patient sponsored studies and the patients pay for both treatment and travel.

Contact Information:MD Stem CellsSteven Levy MD203-423-9494Contact via Emailwww.mdstemcells.com

Read the full story here: https://www.pr.com/press-release/810435

Press Release Distributed by PR.com

Read more here:
New Treatment Shows Vision Benefit in Age Related Macular Degeneration - Benzinga

News Release

Wednesday, April 15, 2020

NIH-funded study offers new path to modeling eye disease, advancing therapies

Researchers have discovered a technique for directly reprogramming skin cells into light-sensing rod photoreceptors used for vision. The lab-made rods enabled blind mice to detect light after the cells were transplanted into the animals eyes. The work, funded by the National Eye Institute (NEI), published April 15 in Nature. The NEI is part of the National Institutes of Health.

Up until now, researchers have replaced dying photoreceptors in animal models by creating stem cells from skin or blood cells, programming those stem cells to become photoreceptors, which are then transplanted into the back of the eye. In the new study, scientists show that it is possible to skip the stem-cell intermediary step and directly reprogram skins cells into photoreceptors for transplantation into the retina.

This is the first study to show that direct, chemical reprogramming can produce retinal-like cells, which gives us a new and faster strategy for developing therapies for age-related macular degeneration and other retinal disorders caused by the loss of photoreceptors, said Anand Swaroop, Ph.D., senior investigator in the NEI Neurobiology, Neurodegeneration, and Repair Laboratory, which characterized the reprogrammed rod photoreceptor cells by gene expression analysis.

Of immediate benefit will be the ability to quickly develop disease models so we can study mechanisms of disease. The new strategy will also help us design better cell replacement approaches, he said.

Scientists have studied induced pluripotent stem (iPS) cells with intense interest over the past decade. IPSCs are developed in a lab from adult cells rather than fetal tissue and can be used to make nearly any type of replacement cell or tissue. But iPS cell reprogramming protocols can take six months before cells or tissues are ready for transplantation. By contrast, the direct reprogramming described in the current study coaxed skin cells into functional photoreceptors ready for transplantation in only 10 days. The researchers demonstrated their technique in mouse eyes, using both mouse- and human-derived skin cells.

Our technique goes directly from skin cell to photoreceptor without the need for stem cells in between, said the studys lead investigator, Sai Chavala, M.D., CEO and president of CIRC Therapeutics and the Center for Retina Innovation. Chavala is also director of retina services at KE Eye Centers of Texas and a professor of surgery at Texas Christian University and University of North Texas Health Science Center (UNTHSC) School of Medicine, Fort Worth.

Direct reprogramming involves bathing the skin cells in a cocktail of five small molecule compounds that together chemically mediate the molecular pathways relevant for rod photoreceptor cell fate. The result are rod photoreceptors that mimic native rods in appearance and function.

The researchers performed gene expression profiling, which showed that the genes expressed by the new cells were similar to those expressed by real rod photoreceptors. At the same time, genes relevant to skin cell function had been downregulated.

The researchers transplanted the cells into mice with retinal degeneration and then tested their pupillary reflexes, which is a measure of photoreceptor function after transplantation. Under low-light conditions, constriction of the pupil is dependent on rod photoreceptor function. Within a month of transplantation, six of 14 (43%) animals showed robust pupil constriction under low light compared to none of the untreated controls.

Moreover, treated mice with pupil constriction were significantly more likely to seek out and spend time in dark spaces compared with treated mice with no pupil response and untreated controls. Preference for dark spaces is a behavior that requires vision and reflects the mouses natural tendency to seek out safe, dark locations as opposed to light ones.

Even mice with severely advanced retinal degeneration, with little chance of having living photoreceptors remaining, responded to transplantation. Such findings suggest that the observed improvements were due to the lab-made photoreceptors rather than to an ancillary effect that supported the health of the hosts existing photoreceptors, said the studys first author Biraj Mahato, Ph.D., research scientist, UNTHSC.

Three months after transplantation, immunofluorescence studies confirmed the survival of the lab-made photoreceptors, as well as their synaptic connections to neurons in the inner retina.

Further research is needed to optimize the protocol to increase the number of functional transplanted photoreceptors.

Importantly, the researchers worked out how this direct reprogramming is mediated at the cellular level. These insights will help researchers apply the technique not only to the retina, but to many other cell types, Swaroop said.

If efficiency of this direct conversion can be improved, this may significantly reduce the time it takes to develop a potential cell therapy product or disease model, said Kapil Bharti, Ph.D., senior investigator and head of the Ocular and Stem Cell Translational Research Section at NEI.

Chavala and his colleagues are planning a clinical trial to test the therapy in humans for degenerative retinal diseases, such as retinitis pigmentosa.

The work was supported by grants EY021171, EY025667, EY025905, and EY025717 and NEI Intramural Research Program grants ZIAEY000450, ZIAEY000474 and ZIAEY000546.

The University of North Texas has a patent pending on the chemical reprogramming method reported in this paper. CIRC Therapeutics is a start-up company that plans to commercialize treatments using the technology.

This press release describes a basic research finding. Basic research increases our understanding of human behavior and biology, which is foundational to advancing new and better ways to prevent, diagnose, and treat disease. Science is an unpredictable and incremental process each research advance builds on past discoveries, often in unexpected ways. Most clinical advances would not be possible without the knowledge of fundamental basic research.

NEI leads the federal governments research on the visual system and eye diseases. NEI supports basic and clinical science programs to develop sight-saving treatments and address special needs of people with vision loss. For more information, visit https://www.nei.nih.gov.

About the National Institutes of Health (NIH):NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.

NIHTurning Discovery Into Health

Mahato B, Kaya KD , Fan Y, Sumien N, Shetty RA, Zhang W, Davis D, Mock T , Batabyal S, Ni A, Mohanty S, Han Z, Farjo R, Forster M, Swaroop A and Chavala SH. Pharmacologic fibroblast reprogramming into photoreceptors restores vision. Published online April 15, 2020 in Nature.http://dx.doi.org/10.1038/s41586-020-2201-4

###

See more here:
Researchers restore sight in mice by turning skin cells into light-sensing eye cells - National Institutes of Health

More than five million Americans, mostly sixty-five or older, suffer from Alzheimers disease (AD), and that number is expected to triple by 2060, as todays twenty-somethings become seniors. No treatments exist for this devastating disease, and its root causes remain as tangled as the curious brain deformities that German physician Alois Alzheimer first described in 1906.

Now a team of Tufts researchers from the School of Medicine and the School of Engineering has received a five-year, $5 million grant from the National Institute on Aging, part of the National Institutes of Health, to study the role of different cell types and mutations in AD. They will use a unique bioengineered mini brain that realistically simulates the human brain environment for years.

The work, which builds on years of collaboration among the researchers, will overcome two traditional stumbling blocks to such studies: the limited relevance of animal models and the inability of cell culture systems to reproduce the physiology of the human brain. While age is the biggest risk factor for AD, genetics also plays a role. Scientists have uncovered twenty gene variants that increase the risk of AD, said Giuseppina Tesco, professor of neuroscience and lead investigator on the research, who has devoted her career to studying the disease.

Recent studies show that most of the genes that carry these variants are expressed in glial cells, particularly astrocytes and microglial cells. Once dismissed as onlookers in the brain, glia are now front and center in Alzheimers research said glia expert Philip Haydon, a principal investigator on the project. Haydon, the Annetta and Gustav Grisard Professor of Neuroscience, likens these cells to the pit crew for the flashy race-car-like neurons, supporting top performance by, for example, preventing buildup of protein plaques.

But unlike neurons, human glial cells behave very differently from those of other mammals. What we can learn from mouse models is very limited. It is very important to study these genes in human cells, said Tesco. And we need to do this over time. It may take months to see the effect of genetic variation.

The Tufts team will use cells derived from patients with AD as well as healthy subjects, drawing on advanced stem cell technology that makes it possible to reverse engineer human primary cells into induced pluripotent stem cells, which can then differentiate into neurons, astrocytes, and microglia.

These glia and other brain cells will grow on a unique three-dimensional doughnut-shaped scaffold made of porous silk and collagenwhat the researchers have dubbed a mini brain. Bioengineer David Kaplan, Stern Family Professor and a principal investigator on the grant, and his team have spent six years perfecting the mini brain for research on AD, traumatic brain injury, and brain cancer.

This model allows us to put cells where we want, determine ratios of different cells to use in the system, and control interactions, so we can study electrophysiology, synaptic activity, and other functions as the tissue ages, said Kaplan. That control over the long term supports exploration of age-related questions about disease progression and contributes to reproducibility, a scientific pillar. Past experiments using these mini brains have mimicked structural and functional features and neural activity for up to two years.

In contrast, a two-dimensional culture systemlike the proverbial petri dishwont replicate the complexities of multiple cell types and physiologies. And organoidssimplified organs in miniature now in vogueare subject to cellular death after a few weeks or months.

To complement the in vitro studies with the scaffolds, scientists in Haydons lab will transplant some of the human cells, both mutated and normal, into mice. As they grow, the human glia cells will replace the mouse cells, giving researchers an opportunity to study human brain function. This is the first step towards translational studies, said Haydon.

The grant complements donations from Tufts alumni, parents, friends, and other private individuals who have experienced the pain of Alzheimers disease in their own lives. Donor dollars really got some of our early, exploratory work up and running, said Haydon. Now we are building on that.

The NIH support is a bright spot at a time when COVID-19 has forced Tufts scientists, like their peers around the world, to halt laboratory research, sometimes losing years of work.

Tesco said that while it is difficult to be away from her lab, safety is more important than anything else. Im from Italy, where we have more than 22,000 deaths, she said. Being healthy and having the possibility to continue to do some work, I feel lucky. Well be in the best position possible when were ready to start because well be able to start something completely new and very exciting.

Kim Thurler can be reached at kimberly.thurler@tufts.edu.

See original here:
Stem Cells and Silk Make a New Way to Study the Brain - Tufts Now

NEW YORK, April 15, 2020 /PRNewswire/ -- The stem cell therapy market was valued at US$ 1,534.55 million in 2019 and is estimated to reach US$ 5,129.66 million by 2027; it is expected to grow at a CAGR of 16.7% from 2020 to 2027.

Read the full report: https://www.reportlinker.com/p05882135/?utm_source=PRN

The increasing awareness related to the stem cells therapy in effective disease management and growing demand for regenerative medicines are the key factor driving the stem cell therapy market. However, high cost related of the stem cell therapy limits the growth of the market.Stem cell research has been widely investigated globally for various medical applications, especially for the treatment of humans.This raises the importance of creating public awareness about stem cell research and its clinical potential.

The main role of stem cells is in the replacement of dying cells and reconstruction of damaged tissues. Based on the extensive stem cell research, many scientists have claimed that these cells could probably be used in the treatment of various diseases, including cancer and cardiovascular disease.There is a large number of potential treatment procedures that are undergoing clinical trials, and a notably few stem cell therapies have won FDA (i.e., US Food and Drug Administration) approval for clinical usage. For instance, in 2019, the FDA approved Fedratinib for the first-line treatment for myelofibrosis. Moreover, stem cell therapies are widely used in bone marrow transplantation, and these therapies have benefited thousands of people suffering from leukemia. Hematopoietic stem cells are used for treating more than 80 medical diseases, including immune system disorders, blood disorders, neurological disorders, metabolic disorders, genetic disorders, and several types of cancers, such as leukemia and lymphoma; this is also likely to boost the demand for this treatment procedure during the forecast period. Researchers are further investigating the use of stem cell therapies in the treatment of autoimmune disorders.

The global stem cell therapy market has been segmented on the basis of type, treatment, application type, and end user.Based on type, the market has been segmented into adult stem cell therapy, induced pluripotent stem cell therapy, embryonic stem cell therapy, and others.

The adult stem cell therapy held the largest share of the market in 2019; however, induced pluripotent stem cell therapy is estimated to register the highest CAGR in the market during the forecast period.Based on treatment, the stem cell therapy market has been segmented into allogeneic and autologous.

The allogeneic segment held a larger share of the market in 2019; however, the market for the autologous segment is expected to grow at a higher CAGR during the forecast period.Based on application type, the stem cell therapy market has been segmented into musculoskeletal, dermatology, cardiology, drug discovery and development, and other applications.

The musculoskeletal segment held the largest share of the stem cell therapy market in 2019, whereas the drug discovery and development segment is expected to report the highest CAGR during 20202027. Based on end user, the market has been segmented into academic and research institutes, and hospitals and specialty clinics. The academic & research institutes held the largest share of the market in 2019, and it is also expected to report the highest CAGR during the forecast period.Several essential secondary sources referred to for preparing this report are the FDA, World Health Organization (WHO), Organisation for Economic Co-operation and Development, National Institutes of Health, Spanish Agency for Medicines (AEMPS), Japanese Society for Regenerative Medicine, and Indian Council of Medical Research, among others.

Read the full report: https://www.reportlinker.com/p05882135/?utm_source=PRN

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

View original content:http://www.prnewswire.com/news-releases/stem-cell-therapy-market-to-2027---global-analysis-and-forecasts-by-type-treatment-application-end-user-and-geography-301041155.html

SOURCE Reportlinker

More:
Stem Cell Therapy Market to 2027 - Global Analysis and Forecasts by Type; Treatment; Application; End User, and Geography - P&T Community